Atea closes $215m Series D round to support Covid-19 trials
The Covid-19 pandemic has encouraged Atea to re-orient its work in the direct-acting antiviral space...
Read More...
Focus:
-
![Generics Covid-19]()
Generics and the Covid-19 pandemic: Q&A with Accord’s Dr Anthony Grosso
Like all industries, the pharma industry has been disrupted by the Covid-19 pandemic. The generics...
Read More...
-
![Veeva R&D summit patients]()
Veeva R&D summit 2020: putting patients at the centre of clinical research
Despite the Covid-19 pandemic, Veeva held its European R&D summit in May where it launched...
Read More...
-
![PTC acquires Censa]()
PTC acquires Censa: diversifying into metabolic disease
New Jersey-based PTC Therapeutics has acquired another rare disease company, Censa Pharmaceuticals, for $10m in...
Read More...
-
![AbCellera Covid-19]()
Canadian Government invests $175.6m in AbCellera’s Covid-19 response
AbCellera has received $175.6m through the Canadian Government’s Strategic Innovation Fund to support the development...
Read More...
-
![launch a drug in a pandemic Immunomedics]()
How to launch a drug in a pandemic with Immunomedics
During the ongoing Covid-19 pandemic, the FDA has continued in its normal role of approving...
Read More...
-
![AbbVie Allergan acquisition]()
AbbVie acquires Allergan: unpicking the year-long approval process
AbbVie’s $63bn acquisition of Allergan has been in the works since June 2019. It aims...
Read More...
-
![Covid-19 UK ACCORD]()
Covid-19 pandemic: a deep dive into the UK’s ACCORD programme
To accelerate drugs through the early stages of clinical development and into large-scale UK studies,...
Read More...
-
![Covid-19 treatment IFPMA]()
Covid-19 pandemic: investigating the treatment landscape with IFPMA
It is going to take at least a year for a Covid-19 vaccine to be...
Read More...
-
![Vertex Affinia gene therapy]()
Vertex-Affinia partnership: expanding the gene therapy toolkit
Building on the success of its gene-targeted cystic fibrosis therapies, Vertex has begun to expand...
Read More...
